Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 4, 1999, Pages 391-400

  Kovarik, John M ^a,b   Rigaudy, Laurence ^a   Guerret, Madeleine ^a   Gerbeau, Christophe ^a   Rost, Karl Ludwig ^a  

^a PAREXEL INTERNATIONAL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; GLYCOPROTEIN P; VALSPODAR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; ELECTROCARDIOGRAM; FEMALE; HUMAN; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULSE RATE; STEADY STATE;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CARDIOTONIC AGENTS; CYCLOSPORINS; DIGOXIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; P-GLYCOPROTEIN; REFERENCE VALUES;

EID: 0032698091     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1053/cp.1999.v66.a101462     Document Type: Article

References (23)

1. 1. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Tastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-8.
2. 2. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 1998;251:252-61.
3. 3. Sikic BI. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993;11:1629-35.
4. 4. Boesch D, Gareriaux C, Jachez B, Pourtier-Mandanedo A, Bollinger P, Loor F. In vivo circumvention of P-gp-mediated multidrug resistance of tumour cells with SDZ PSC 833. Cancer Res 1991;51:4226-33.
5. 5. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997;40(suppl):S13-9.
6. 6. DeLannoy IAM, Silverman M. The mdr1 gene product P-glycoprotein mediates the transport of the cardiac glycoside, digoxin. Biochem Res Commun 1992;30:551-7.
7. 7. Bigger JT Jr. The quinidine-digoxiri interaction. Int J Cardiol 1981;1:109-16.
8. 8. Rodin SM, Johnson BF. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet 1988;15:227-44.
9. 9. Dorian P, Strauss M, Cardella C, David T, East S, Ogilvie R. Digoxin-cyclosporine interaction: severe digitalis toxicity after cyclosporine treatment. Clin Invest Med 1988;11:108-12.
10. 10. Preiss R. P-glycoprotein and related transporters. Int J Clin Pharmacol Ther 1998;36:3-8.
11. 11. Mueller EA, Kovarik JM, Ueresin Y, Preisig-Flueckiger SS, Hensel S, Luecker PW, et al. Optimizing the absorption of valspodar, a P-glycoprotein modulator; I: selecting an oral formulation and exploring its clinical pharmacokmetics/dynamics. J Clin Pharmacol 1997;37:1001-8.
12. 12. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker; 1982.
13. 13. Ahnve S. Correction of the QT interval for heart rate: review of different formulas and the use of Bazett's formula in myocardial infarction. Am Heart J 1985;109:568-74.
14. 14. Schuirmann DJ. A comparison of the two one-sided test procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657-80.
15. 15. Nelson LS. Testing two correlated variances. Technometrics 1965;7:447-9.
16. 16. Gaveriaux C, Boesch D, Jachez B, Bollinger P, Payne T, Loor F. SDZ PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier. J Cell Pharmacol 1991;2:225-34.
17. 17. Boote DJ, Dennis IF, Twenty mann PR, Osborne RJ, Laburte C, Hensel S, et al. A phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance. J Clin Oncol 1996;14:610-8.
18. 18. Sonneveld P, Marie JP, Huisman C, Verhoff A, Schoester M, Faussat AM, et al. Reversal of multidrug resistance by SDZ PSC 833 combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma: a phase I study. Leukemia 1996;10:1741-50.
19. 19. Loi CM, Knowlton PW, Stern R, Randinitis EJ, Vassos AB, Koup JR, et al. Effect of troglitazone on steady-state pharmacokinetics of digoxin. J Clin Pharmacol 1998;38: 178-83.
20. 20. Dockens RC, Greene DS, Barbhaiya RH. Assessment of pharmacokinetic and pharmacodynamic drug interactions between nafazodone and digoxin in healthy male volunteers. J Clin Pharmacol 1996;36:160-7.
21. 21. Okamura N, Hirai M, Tanigawara Y, Tanaka K, Yasuhara M, Ueda K, et al. Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney. J Pharmacol Exp Ther 1993;266:1614-9.
22. 22. Cavet ME, West M, Simmons NL. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 1996;118:1389-96.
23. 23. Mayer U, Wagenaar E, Doborek B, Beijnen JH, Borst P, Schinkel AH. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997;100:2430-6.